HANXBIO-B (3378.HK): Signs Strategic Cooperation and XtalPi Science Platform Licensing Deals With XtalPi
- Partner Shenzhen XtalPi Technology is an independent third party; deals cover a framework pact and platform licence.
- Focus is AI for Science in antibody design, innovative molecule design and R&D process optimization.
- Procurement scale, service scope and commercial terms will be set by later orders or agreements.
NewTimeSpace News: On 21 September 2026, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (stock code: 3378) said in a voluntary announcement that it signed a strategic cooperation framework agreement and an XtalPi Science technology platform usage authorization agreement (together, the "Agreements") with Shenzhen XtalPi Technology Co., Ltd. (an independent third party) to explore applications of AI for Science in antibody design, innovative molecule design and drug R&D process optimization.
Under the Agreements, the Company plans to procure and use XtalPi Science platform services and usage quotas as needed, with XtalPi providing platform capabilities and technical support. The initial application scenarios to be explored include using AI models, computing power and agents to assist the design, analysis and optimization of biologics candidate molecules; designing XDC payloads with special functions; and custom-designing other candidate molecules and key functional modules.
Centred on the commercial procurement and application of XtalPi Science products and services, the cooperation aims to optimize the Company's biologics screening and molecule optimization process, with the potential to raise R&D efficiency and success rates, shorten R&D cycles, cut R&D costs and accelerate FIC and BIC drug development. Founded in 2014, Hanx is an innovative biotech company focused on structural biology, translational medicine and clinical development.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- OCI INTL (00329.HK): H1 Revenue Down 18% to HK$28.2m, Period Loss Widens to HK$3.94m
- JIAHUA STORES H (00602.HK): Delayed Despatch of Circular on Disposal of Leasehold Improvements to 23 Oct
- CHOW SANG SANG (0116.HK): H1 Turnover Up 17% to HK$12.878bn, Profit Attributable Up 139%
- CICC (03908.HK): Launches Seventh Tranche of 2026 Corporate Bonds, Size Up to RMB 6 Billion
- CPIC (02601.HK): H1 Net Profit Attributable to Parent Up 10.4% to RMB 30.775 Billion, Interim Dividend RMB 0.42 Per Share
